Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 36.38 billion. The enterprise value is 46.56 billion.

Market Cap	36.38B
Enterprise Value	46.56B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class	11.66M
Shares Outstanding	11.66M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	4.73M

Valuation Ratios

The trailing PE ratio is 20.32.

PE Ratio	20.32
Forward PE	n/a
PS Ratio	0.69
PB Ratio	0.88
P/TBV Ratio	0.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.79, with an EV/FCF ratio of -10.30.

EV / Earnings	26.01
EV / Sales	0.89
EV / EBITDA	20.79
EV / EBIT	n/a
EV / FCF	-10.30

Financial Position

The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.43.

Current Ratio	2.17
Quick Ratio	1.11
Debt / Equity	0.43
Debt / EBITDA	7.92
Debt / FCF	-3.92
Interest Coverage	-0.98

Financial Efficiency

Return on equity (ROE) is 4.43% and return on invested capital (ROIC) is -0.48%.

Return on Equity (ROE)	4.43%
Return on Assets (ROA)	-0.38%
Return on Invested Capital (ROIC)	-0.48%
Return on Capital Employed (ROCE)	-0.75%
Revenue Per Employee	304.85M
Profits Per Employee	10.41M
Employee Count	172
Asset Turnover	0.74
Inventory Turnover	1.63

Taxes

In the past 12 months, Seoul Pharma has paid 100.47 million in taxes.

Income Tax	100.47M
Effective Tax Rate	5.31%

Stock Price Statistics

The stock price has decreased by -10.53% in the last 52 weeks. The beta is 0.51, so Seoul Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	-10.53%
50-Day Moving Average	3,099.50
200-Day Moving Average	3,277.08
Relative Strength Index (RSI)	51.87
Average Volume (20 Days)	19,134

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 52.43 billion and earned 1.79 billion in profits.

Revenue	52.43B
Gross Profit	32.24B
Operating Income	-432.63M
Pretax Income	1.89B
Net Income	1.79B
EBITDA	2.24B
EBIT	-432.63M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 7.55 billion in cash and 17.73 billion in debt, giving a net cash position of -10.18 billion or -873.34 per share.

Cash & Cash Equivalents	7.55B
Total Debt	17.73B
Net Cash	-10.18B
Net Cash Per Share	-873.34
Equity (Book Value)	41.30B
Book Value Per Share	n/a
Working Capital	19.30B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.98 billion and capital expenditures -544.53 million, giving a free cash flow of -4.52 billion.

Operating Cash Flow	-3.98B
Capital Expenditures	-544.53M
Free Cash Flow	-4.52B
FCF Per Share	-387.74

Full Cash Flow Statement

Margins

Gross margin is 61.48%, with operating and profit margins of -0.83% and 3.41%.

Gross Margin	61.48%
Operating Margin	-0.83%
Pretax Margin	3.61%
Profit Margin	3.41%
EBITDA Margin	4.27%
EBIT Margin	-0.83%
FCF Margin	n/a

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	4.92%
FCF Yield	-12.43%

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2004
Split Type	Forward
Split Ratio	2

Scores

Seoul Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.84
Piotroski F-Score	2